TNDM - DexCom Tandem Diabetes fall on Apple glucose monitor new team lead
2023-09-14 16:28:35 ET
More on DexCom, Tandem Diabetes, Insulet
- Why DexCom May Be Up To 40% Undervalued
- Tandem Diabetes: Cash Flow And Profitability Trends A Drag On Equity Performance, Reiterate Hold
- Insulet: Losing More Weight
- Dexcom Denies Weight Loss Drug Threat To CGM Sales - I'd Be A Little Concerned
- Insulet: High Growth Not Translating To Economic Value For Shareholders (Rating Downgrade)
For further details see:
DexCom, Tandem Diabetes fall on Apple glucose monitor new team lead